LD-2 disclosure · 3rd Quarter - Termination Amendment
MYRIAD GENETIC LABORATORIES, INC.
via MYRIAD GENETIC LABORATORIES, INC.
Client
- Name
- MYRIAD GENETIC LABORATORIES, INC.
- Location
- District of Columbia · United States of America
Registrant
- Firm
- MYRIAD GENETIC LABORATORIES, INC.
- Description
- Development and marketing of molecular diagnostics
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesMedicare/Medicaid
Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests
LobbyistsKIMBERLY LINTHICUM
Covered position (KIMBERLY LINTHICUM): Leg Director, Rep Bob Franks (1997-2000) Leg Correspondent, Rep Charles Taylor (1997) Leg Correspondent, Rep Bill Martini (1995-1996)
TargetedSENATE · HOUSE OF REPRESENTATIVES · Food & Drug Administration (FDA) · Centers For Medicare and Medicaid Services (CMS)
Medical/Disease Research/Clinical Labs
Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)
LobbyistsKIMBERLY LINTHICUM
Covered position (KIMBERLY LINTHICUM): Leg Director, Rep Bob Franks (1997-2000) Leg Correspondent, Rep Charles Taylor (1997) Leg Correspondent, Rep Bill Martini (1995-1996)
TargetedSENATE · HOUSE OF REPRESENTATIVES · Food & Drug Administration (FDA) · Centers For Medicare and Medicaid Services (CMS)